Let's tell the full story
Like I said before, it's device sales, not the pentrox sales.
I have said before that the pentrox sales would be seen in FY19 as they prep FY18 for growth, which is why we see lots of approvals.
Getting those approvals requires spending $$, which is why we see lower profits. If want short term profits, then MVP should not spend any on getting those approvals, and certainly not progress any payments to CSIROl; of which they were successful in a few trials .
Success in CSIRO trial:
https://hotcopper.com.au/threads/an...w-manufacturing-technology-lidocaine.4029076/
Ann: Trading Update, page-44
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.25M | |||
| Open | High | Low | Value | Volume |
| 45.5¢ | 46.0¢ | 45.5¢ | $4.937K | 10.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 60988 | 45.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 60000 | 7 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| MVP (ASX) Chart |